Osivax has licensed an influenza vaccine from GC Biopharma, positioning the biotech to build on early evidence that its midphase candidate complements traditional flu shots.
Osivax has licensed an influenza vaccine from GC Biopharma, positioning the biotech to build on early evidence that its midphase candidate complements traditional flu shots.